Keeping pace with PBAC and MSAC key dates
Staying ahead in the pharma and medtech sectors requires a deep understanding of regulatory and advisory timelines, such as those set by […]
Tag: HTA
Positioning Australia’s Life Sciences Industry for Global Success
Australia is a leader in niche life science segments with strong global markets, including plasma therapies, hearing implants, and sleep apnoea devices. […]
Free market access strategy advisory for medtech startups
Pulse Economics is offering free 30-minute consultations to help you navigate the complexities of market access and reimbursement in Australia. Gain insights […]
Reimbursement process for high cost highly specialised therapies in public hospitals
In today’s rapidly evolving healthcare landscape, navigating the reimbursement pathway for high-cost highly specialised therapies presents a formidable challenge. These treatments, including […]
Environmental Sustainability in Health Technology Assessment (HTA)
Two environmental sustainability in healthcare conferences/webinars in one week? You must be joking. But no, it’s no joke. ISPOR Australia Chapter: Incorporating […]
Unlocking Consumer Insights in Health Technology Assessment
Ever asked for feedback? The results can often be quite surprising. We might find ourselves pondering questions like, “Why did they focus […]
Medicines Australia Horizon Scanning Forum
Our Medicines Australia Horizon Scanning Forum presentation highlighted the journey of AI-enabled IVD from Parkinson’s prognosis to broader neurological applications. As advancements […]
HTA Policy and Methods Review – Draft discussion papers
The Australian Government Department of Health and Aged Care has published seven draft discussion papers as part of its HTA Policy and […]
ISPOR-AC HTA Harmonisation Workshop
Thank you to ISPOR Australia Chapter for hosting the HTA Harmonisation Workshop yesterday in Sydney. The interactive panel discussions highlighted the lack […]